Cytomedix Announces Publication in American Heart Journal BiotechStockTrader.com OB) (the “Company”), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that positive data from a Phase 1 clinical trial of ALD-201 to treat ischemic heart failure were ... Cytomedix Announces Publication in American Heart Journal Highlighting ... |
